HeadCheck completes CTA Accelerator and Dose of the Valley in San Francisco


February 28, 2017 — HeadCheck Health was selected as a participant in the Canadian Technology Accelerator San Francisco (CTA SF) Life Sciences program, run by the Canadian Consulate in San Francisco in partnership with Spire Bioventures. The Canadian Technology Accelerator (CTA) program, which began in November 2016 and ran through the end of February 2017, provides Canadian high-growth technology companies with exposure to global markets, partners and investors. The San Francisco region is home to some of the largest and most active life sciences-oriented companies and venture capital firms. CTA SF Life Sciences is designed to provide targeted education and connectivity to help CEOs and Founders of Canadian high potential growth life sciences companies accelerate the growth of their companies. Out of 60 applicants across Canada, only 7 were selected to participate by a high-level review committee.

“This was an excellent opportunity to work with and learn from some of San Francisco’s best Life Science leaders.” said Kerry Costello, COO of HeadCheck Health. “Having our feet on the ground, expanding our network, and tapping into the resources and education offered through the program was an irreplaceable experience. The timing was perfect for HeadCheck Health to begin to develop a presence in the U.S. market to advance its objectives.”



The Accelerator program ended this past week at Dose of the Valley in San Francisco on February 22nd and 23rd, 2017. Dose of the Valley is a two-day program organized by the Canadian Consulate in San Francisco. The annual by invitation-only event connects Canada’s most promising life science companies through roundtable discussions, industry-led workshops, one-on-one mentorship, an investor/partnering pitch session, and a networking reception.

Latest from the HEADCHECK blog